13 results about "Mucosal immunity" patented technology

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

Provided are a composition for preventing and treating an oral disease or condition, a preparation method therefor, and the use thereof. The composition comprises extracellular vesicles derived from oral pathogenic bacteria. The extracellular vesicles are nanoscale vesicles rich in immune activation and defensive factors against pathogenic bacterial infection. Upon administration via the oral mucosa into a body, the vesicles are passively aimed at lymph nodes associated with the oral mucosa to induce the expression of a mucosal immunity-specific antibody, thereby enhancing immune defense against pathogenic bacteria. The extracellular vesicles of oral pathogenic bacteria are coated with a calcium phosphate shell, and the shell is soluble only under acidic conditions and degrades only after the extracellular vesicles are aimed at the lymph nodes and are phagocytosed into lysosomes of dendritic cells, thereby avoiding inflammatory reactions in an administration area. By using a sublingual disintegrating tablet as the form of administration, the bioavailability of a vaccine can be enhanced while achieving the local administration at the mucosa and activating mucosal immunity. Moreover, the composition is convenient to administer, which is conducive to the diagnosis and treatment of oral bacterial infectious diseases.

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

Described herein are vaginal lactobacilli strains that actively modulate mucosal immunity, and compounds produced by these bacteria that exhibit anti-inflammatory activity.

This invention discloses a recombinant lactic acid bacteria expressing a truncated avian adenovirus Hexon protein, its construction method, and its applications, belonging to the field of biomedical technology. This invention is the first to construct recombinant lactic acid bacteria strains pNZ8149-FAdV4ΔHexon / NZ3900 and pNZ8149-FAdV8bΔHexon / NZ3900 expressing the truncated avian adenovirus Hexon protein. SDS-PAGE and Western blotting analyses showed that the exogenous genes FADV4-ΔHexon and FADV-8bΔHexon were successfully expressed in *Lactococcus lactis* and exhibited reactivity. Oral immunization of one-day-old chicks showed that oral administration of the recombinant lactic acid bacteria induced humoral and cellular immunity, as well as local mucosal immunity. The results indicate that the recombinant constitutive lactic acid bacteria prepared in this invention can enhance the immunity of chicks.

The application provides an antigen epitope polypeptide and a paralichthys ovatus mucin Muc1 specific antibody prepared by the antigen epitope, a B cell epitope from the paralichthys ovatus Muc1 protein is identified through antigen epitope screening, and the amino acid sequence is SEQ ID NO:1. After the epitope is coupled with a KLH carrier protein, a New Zealand white rabbit is immunized, and a rabbit anti-paralichthys ovatus Muc1 polyclonal antibody is successfully prepared. The antibody can specifically recognize the Muc1 protein in paralichthys ovatus mucosa tissue and positive mucous cells, and provides an important detection tool for studying the function mechanism of mucous cells in fish mucosal immunity.

The application belongs to the field of immunology and relates to an mRNA delivery carrier, a preparation method and application of an oral vaccine. A calcium alginate microsphere and a cholic acid-fluorine co-modified polyethyleneimine (DFP) form a double protection system, the compact crosslinked structure of the calcium alginate microsphere resists the acid-base environment of the gastrointestinal tract and nuclease degradation, and the complex formed by the DFP and the mRNA can further prevent the mRNA from being enzymatically degraded. The application provides preparation of an oral mRNA delivery system for activating intestinal mucosal immunity and application of the oral mRNA delivery system in a diarrhea vaccine, provides effective protection against porcine diarrhea coronavirus infection, and provides a new idea for research and development of intestinal mucosal vaccines.

The present application belongs to the technical field of genetic engineering, and particularly relates to a recombinant plant lactobacillus for preventing and controlling chicken necrotic enteritis as well as a preparation method and application thereof. The present application provides an oral vaccine carrier capable of co-expressing multiple key virulence factor antigens (FimB, NetB, CnaA, FBA) of Clostridium perfringens, and the efficiency of the vaccine carrier being recognized and taken by professional antigen presenting cells is significantly improved through fusion of dendritic cell (DC) targeting molecules (nanobody Phi74), so as to enhance immunogenicity. Immunization of animals using the recombinant lactobacillus can induce mucosal immunity, cellular immunity and humoral immunity response, and comprehensively enhance the immune ability of the body, thereby establishing a safe, efficient and suitable oral immunization scheme for large-scale breeding for treating chicken necrotic enteritis.

The application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis belongs to the field of biomedical technology. This invention addresses the limitations of existing treatments for inflammatory bowel disease (IBD), which suffer from limited efficacy, significant side effects, and difficulty in targeting and repairing the intestinal immune barrier. It provides the application of recombinant ultra-high molecular weight hyaluronic acid in regulating intestinal immunity in colitis. This recombinant ultra-high molecular weight hyaluronic acid can activate the intestinal IgA-producing immune network, regulate inflammation-related genes, and repair the physical and immune barriers of the colonic mucosa, thus exhibiting a superior protective effect against colitis compared to conventional hyaluronic acid, providing a new candidate drug for the treatment of IBD.

The application provides an antigen epitope polypeptide and a paralichthys dentatus BMP2 protein specific antibody prepared by the antigen epitope, designs an antigen epitope through bioinformatics analysis, adopts a segmented recombination expression strategy to obtain BMP2-N and BMP2-C recombination proteins in view of the low expression efficiency of full-length BMP2 protein in a prokaryotic system, and uses the recombination proteins as immunogens to prepare polyclonal antibodies. It is verified through immunoblotting and immunofluorescence that the prepared antibodies can specifically recognize the paralichthys dentatus BMP2 protein, have high affinity and good reaction activity, and effectively avoid the problems of false negative or low signal caused by insufficient cross reactivity of the antibodies. On this basis, a BMP2 immunological detection kit is constructed, precise positioning and expression analysis of the BMP2 protein in mucous membrane tissues such as skin, gill and intestinal tract of the paralichthys dentatus can be realized. The antibody and the kit provide a reliable tool for studying the role of BMP2 in fish mucosal immunity, and have important scientific research value and application prospect.

The application discloses a pet immune and beautiful hair composition with skin mucosa immune enhancement function and a preparation method and application thereof, and belongs to the technical field of pet food. The composition is a "core-shell-net" microcapsule structure: the lipid phase core contains functional oil and DL-methionine; a polysaccharide grid composed of sodium hyaluronate and beta-1, 3-D-glucan provides physical confinement and mechanical support; a shell layer formed by complex coagulation of lactoferrin and sodium hyaluronate realizes low release in the stomach and intestinal targeted release, and chenopodium quinoa powder is embedded in the shell layer to construct a pre-antioxidant barrier, and lactobacillus plantarum and lactobacillus acidophilus are embedded in the shell layer to realize the protection of probiotics. The application realizes high retention rate of active ingredients under baking processing, significantly prolongs the oxidation induction period and realizes targeted delivery, and ensures high survival rate of probiotics, significantly improves pet hair luster and reduces hair loss by enhancing skin mucosa immunity, and realizes the synergistic delivery of multiple components.

The application belongs to the technical field of biological feed, and discloses a composition for improving immunity of young pets and application thereof, wherein the composition comprises soybean peptides and beta-glucan, and the mass ratio of the soybean peptides to the beta-glucan is 5:1-10:1. Experiments show that the composition can significantly improve the weight growth rate of young pets, improve the body condition and fecal state, increase the content of serum protein, immunoglobulin and various immune factors, increase the level of fecal secreted immunoglobulin A, and effectively enhance the whole body immunity and intestinal mucosal immunity of young pets. The composition is safe and efficient, low in cost, and has strong compatibility with pet daily food, and is suitable for preparing pet food, animal feed and related additives, and can be widely used for immune enhancement and health care of various young pets such as cats and dogs, and solves the technical problems of single function, poor effect and high cost of existing products.